Skip to main content

Rare kidney & urinary condition

Tuberous sclerosis and the kidneys

Tuberous sclerosis complex causes benign kidney tumours (angiomyolipomas) and cysts in most affected adults; bleeding from large angiomyolipomas is the main danger, and mTOR inhibitor therapy shrinks them.

Key points

The essentials at a glance.

What to look out for, how the diagnosis is confirmed, who looks after it, and the options that exist.

  • 01

    Angiomyolipomas grow through life; risk of bleeding rises with size (classically above 3-4 cm) and with aneurysms within them.

  • 02

    Surveillance MRI of the kidneys every 1-3 years is standard for life.

  • 03

    Everolimus (an mTOR inhibitor) shrinks angiomyolipomas and is preferred over repeated surgery.

  • 04

    Selective embolisation - not nephrectomy - is the emergency and preventive procedure of choice when intervention is needed; preserving kidney tissue is a core principle.

  • 05

    TSC kidneys also develop cysts and, rarely, kidney cancer - unusual-looking lesions merit specialist review. Care sits in TSC clinics coordinating brain, skin, lung and kidney aspects.

Understanding it

What it is, and what happens next.

In plain English - what is going on, how specialists confirm it, and the routes to treatment in the UK.

In tuberous sclerosis, loss of TSC gene function releases the mTOR growth pathway, and the kidney responds by growing angiomyolipomas - benign tangles of vessel, muscle and fat whose fragile aneurysmal vessels can rupture catastrophically. Kidney complications are the leading cause of adult mortality in TSC, which is precisely why structured lifelong surveillance exists.

Adult care centres on the TSC clinic model: scheduled MRI tracks every lesion, everolimus is introduced when angiomyolipomas approach risk thresholds - shrinking them and treating other TSC manifestations simultaneously - embolisation stands ready for bleeding or high-risk lesions, and kidney-sparing principles govern every intervention because these patients need their nephrons for a lifetime of the disease. In many parts of the UK, routine NHS outpatient referrals for problems like this can take several months, whereas an initial appointment with a private consultant is typically available within around two weeks.

A quiet reminder

This guide is for information, not medical advice.

Your GP or specialist knows your history and can tell you which parts apply to you. If in doubt, speak to them.

Published 2026-09-27 · Next review 2027-09-27

Frequently asked

Common questions about Tuberous sclerosis and the kidneys.

Quick, plain-English answers to what people ask us most.

  • How does tuberous sclerosis affect the kidneys?

    Tuberous sclerosis commonly causes benign kidney tumours called angiomyolipomas, and less often kidney cysts, which can grow over time and, if large, carry a risk of bleeding or affecting kidney function.

  • What causes kidney involvement in tuberous sclerosis?

    It results from the same TSC1 or TSC2 gene mutation that drives tumour growth throughout the body, affecting the mTOR cell growth pathway in kidney tissue specifically.

  • What are the symptoms of kidney angiomyolipomas?

    Small tumours often cause no symptoms and are found on routine surveillance imaging; larger ones can cause flank pain, blood in the urine, or, if they bleed, sudden severe pain and low blood pressure requiring emergency care.

  • Are kidney angiomyolipomas dangerous?

    Larger angiomyolipomas (generally over 3-4cm) carry an increased risk of spontaneous bleeding, which can be serious, so regular monitoring and, when needed, preventive treatment is recommended.

  • Can kidney angiomyolipomas be treated to prevent complications?

    Yes, mTOR inhibitor medication can shrink angiomyolipomas and reduce bleeding risk, and for larger or higher-risk tumours, a minimally invasive procedure (embolisation) can reduce blood flow to the tumour to prevent bleeding.

  • How is kidney involvement monitored?

    Regular kidney imaging, usually MRI, is recommended (typically every one to three years, or more frequently if tumours are larger or growing) to track angiomyolipoma size and kidney function.

  • How long does treatment with mTOR inhibitors take to show benefit?

    Tumour shrinkage with mTOR inhibitor medication is usually seen over several months of continuous treatment, with ongoing therapy needed to maintain the benefit.

  • Angiomyolipoma vs kidney cancer - what's the difference?

    Angiomyolipomas are benign (non-cancerous) tumours made of blood vessels, muscle and fat tissue, distinguishable from kidney cancer on characteristic imaging appearances, though very large or atypical-looking lesions occasionally need further assessment to be certain.

  • When is treatment needed for kidney angiomyolipomas?

    Treatment is generally considered when tumours grow beyond about 3-4cm, are causing symptoms, or show worrying features on imaging, to reduce the risk of bleeding.

  • When should I see a specialist about kidney monitoring, and how quickly can I be seen privately?

    Regular specialist nephrology or urology follow-up is recommended for anyone with TSC-related kidney tumours. NHS waits can be lengthy; private specialists experienced in TSC can often see you within about two weeks.